For the year ending 2025-12-31, PBYI had -$39,584K decrease in cash & cash equivalents over the period. $41,731K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 31,111 |
| Depreciation and amortization | 10,938 |
| Stock-based compensation | 6,944 |
| Deferred income taxes | 3,245 |
| Provision for credit loss recovery | -362 |
| Loss on disposal of property and equipment | -4 |
| Loss on impairment of asset | 0 |
| Accounts receivable, net | 21,281 |
| Inventory, net | -3,209 |
| Prepaid expenses and other | 325 |
| Other current assets | 165 |
| Accounts payable | -453 |
| Operating lease assets and liabilities, net | 1,805 |
| Accrued expenses and other | 13,154 |
| Post-marketing commitment liability | -2,412 |
| Net cash provided by operating activities | 41,802 |
| Purchase of property and equipment | 71 |
| Purchase of available-for-sale securities | 108,141 |
| Maturity of available-for-sale securities | 72,024 |
| Purchase of intangible assets | 0 |
| Net cash used in investing activities | -36,188 |
| Net proceeds from shares issued under employee stock plans | 130 |
| Payment of debt | 44,440 |
| Payment of exit costs | 888 |
| Net cash used in financing activities | -45,198 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -39,584 |
| Cash, cash equivalents and restricted cash, beginning of period | 71,310 |
| Cash, cash equivalents and restricted cash, end of period | 31,726 |
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)